BioAtla, Inc. (NASDAQ:BCAB – Get Rating) CEO Jay M. Phd Short acquired 29,082 shares of the stock in a transaction that occurred on Tuesday, June 21st. The stock was purchased at an average price of $2.79 per share, with a total value of $81,138.78. Following the completion of the transaction, the chief executive officer now owns 1,335,674 shares of the company’s stock, valued at $3,726,530.46. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
BCAB traded up $0.06 during midday trading on Thursday, reaching $3.00. 334,368 shares of the company were exchanged, compared to its average volume of 650,754. BioAtla, Inc. has a one year low of $2.01 and a one year high of $47.86. The stock has a market capitalization of $112.24 million, a P/E ratio of -1.02 and a beta of 2.49. The stock’s 50-day simple moving average is $2.88 and its 200 day simple moving average is $7.95.
BioAtla (NASDAQ:BCAB – Get Rating) last issued its earnings results on Thursday, May 5th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.04. Equities analysts expect that BioAtla, Inc. will post -2.72 EPS for the current year.
BCAB has been the subject of a number of research reports. HC Wainwright initiated coverage on BioAtla in a research report on Monday, March 21st. They issued a “buy” rating and a $25.00 price objective for the company. Credit Suisse Group cut BioAtla from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $35.00 to $5.00 in a report on Thursday, May 5th.
About BioAtla (Get Rating)
BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.
- Get a free copy of the StockNews.com research report on BioAtla (BCAB)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.